These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7044387)

  • 1. [Inhibition of nocturnal acid secretion by pirenzepine (author's transl)].
    Dammann HG; Simon B; Müller P; Krüger HJ
    Arzneimittelforschung; 1982; 32(3):309-10. PubMed ID: 7044387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of pentagastrin and insulin-stimulated gastric secretion by pirenzepine in healthy and duodenal ulcer subjects.
    Bianchi Porro G; Prada A; Petrillo M; Grossi M
    Scand J Gastroenterol Suppl; 1979; 57():63-7. PubMed ID: 396660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of pirenzepine and atropine on the transmural gastric mucosal potential difference (author's transl)].
    von Kleist D; Staud R; Stopik D; Hampel HE
    Dtsch Z Verdau Stoffwechselkr; 1980; 40(3-4):110-4. PubMed ID: 6893819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pirenzepine inhibits meal-induced secretory and gastrin responses in dogs (author's transl)].
    Bonfils S; Vatier J; de Mestier P; Accary JP; Kuan T; Bourgeois M
    Gastroenterol Clin Biol; 1982 Jan; 6(1):33-7. PubMed ID: 6896039
    [No Abstract]   [Full Text] [Related]  

  • 5. Inhibition of gastric acid secretion by pirenzepine (LS 519) in man.
    Stockbrügger R; Jaup B; Hammer R; Dotevall G
    Scand J Gastroenterol; 1979; 14(5):615-20. PubMed ID: 493865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition by pirenzepine of nocturnal gastric acid secretion in duodenal ulcer patients.
    Corinaldesi R; Miglioli M; Daniotti S; Stanghellini V; Borghi E; Barbara L
    Scand J Gastroenterol; 1981; 16(7):929-31. PubMed ID: 6895676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Anti-ulcer agent pirenzepine (LS 519)--a tricyclic compound with particular physico-chemical properties (author's transl)].
    Eberlein W; Schmidt G; Reuter A; Kutter E
    Arzneimittelforschung; 1977 Feb; 27(2):356-9. PubMed ID: 577153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of pirenzepine on basal, pentagastrin- and insulin-stimulated gastric acid secretion in patients with peptic ulcer disease.
    Jaup BH; Stockbrügger R; Dotevall G
    Scand J Gastroenterol; 1979; 14(5):621-4. PubMed ID: 493866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic effect of pirenzepine dihydrochloride on gastric ulcer evaluated by a double-blind controlled clinical study. Phase III study.
    Ishimori A; Yamagata S
    Arzneimittelforschung; 1982; 32(5):556-65. PubMed ID: 7049190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of prolonged treatment of pirenzepine 2HCl on gastric secretion and plasma gastrin levels in rats.
    Okabe S; Tabata K; Kawakami M
    Arzneimittelforschung; 1982; 32(6):664-8. PubMed ID: 6896823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pirenzepine in the treatment of duodenal ulcer.
    D'Imperio N; Giuliani Piccari G; Lepore AM; Sarti F; Dal Monte PR
    Scand J Gastroenterol Suppl; 1979; 57():41-4. PubMed ID: 396656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of various secretory inhibitors on peptic activity.
    Gabryelewicz A; Laszewicz W; Sarosiek J
    Scand J Gastroenterol Suppl; 1980; 66():79-85. PubMed ID: 6264587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Actions of pirenzepine-dihydrochloride (LS-519 Cl) on gastric juice secretion, gastric motility and experimental gastric ulcer.
    Matsuo Y; Seki A
    Arzneimittelforschung; 1979; 29(7):1028-35. PubMed ID: 582994
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of pirenzepine, a new gastric acid-inhibiting agent, on exocrine pancreatic secretion in man.
    Brunner H; Veriá M; Polterauer P; Grabner G
    Arzneimittelforschung; 1977; 27(3):684-7. PubMed ID: 577446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Acid secretion and serum gastrin during acute and chronic treatment with pirenzepine in duodenal ulcer (author's transl)].
    Scholten T; Fritsch WP; Müller JE; Hanrath R; Strohmeyer G
    Z Gastroenterol; 1981 Jul; 19(7):323-8. PubMed ID: 6895273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effectiveness of cimetidine, pirenzepine and synthetic secretin on stimulated gastric acid secretion].
    Londong W; Londong V; Prechtl R; Schwanner A
    Z Gastroenterol; 1980 Jun; 18(6):306-13. PubMed ID: 6893378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postprandial pancreatic exocrine secretion in dogs after oral administration of pirenzepine dihydrochloride.
    Madrid JA; Salido GM; Martinez de Victoria E; Mañas M; Mataix FJ
    Arzneimittelforschung; 1985; 35(10):1560-2. PubMed ID: 2416323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of different doses of pirenzepine on gastric secretion stimulated by modified shamfeeding in man.
    Stockbrügger RW; Jaup BH; Dotevall G
    Scand J Gastroenterol Suppl; 1982; 72():111-7. PubMed ID: 6957978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single nocturnal doses of pirenzepine effectively inhibit overnight gastric secretion.
    Howden CW; Burget DW; Silletti C; Hunt RH
    Hepatogastroenterology; 1985 Oct; 32(5):240-2. PubMed ID: 2867023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Inhibitory test of pentagastrin-stimulated gastric secretions in 170 duodenal ulcer patients. Interest for the determination of the dose of gastric inhibitory drugs (author's transl)].
    Toulet J; Pagniez R; Amrani N; Parmentier T; Bosc F
    Gastroenterol Clin Biol; 1981; 5(6-7):646-54. PubMed ID: 6894739
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.